全文获取类型
收费全文 | 105篇 |
免费 | 6篇 |
专业分类
基础医学 | 4篇 |
临床医学 | 3篇 |
内科学 | 66篇 |
皮肤病学 | 1篇 |
外科学 | 4篇 |
药学 | 2篇 |
肿瘤学 | 31篇 |
出版年
2020年 | 2篇 |
2019年 | 2篇 |
2018年 | 4篇 |
2017年 | 4篇 |
2016年 | 6篇 |
2015年 | 2篇 |
2014年 | 5篇 |
2013年 | 4篇 |
2012年 | 9篇 |
2011年 | 8篇 |
2010年 | 3篇 |
2009年 | 5篇 |
2008年 | 2篇 |
2007年 | 4篇 |
2006年 | 10篇 |
2005年 | 12篇 |
2004年 | 4篇 |
2003年 | 10篇 |
2002年 | 7篇 |
2001年 | 1篇 |
1998年 | 3篇 |
1994年 | 1篇 |
1993年 | 2篇 |
1972年 | 1篇 |
排序方式: 共有111条查询结果,搜索用时 15 毫秒
1.
Shin-ichiro Fujiwara Naohito Fujishima Heiwa Kanamori Masumi Ito Tatsuya Sugimoto Shoko Saito Takeshi Sakaguchi Koichi Nagai Hidekazu Masuoka Kazuhiro Nagai Akie Morita Shuichi Kino Asashi Tanaka Yuichi Hasegawa Akihiko Yokohama Keizo Fujino Shigeyoshi Makino Mayumi Matsumoto Kazuo Muroi 《Transfusion and apheresis science》2018,57(6):746-751
Background
Plasma removal by washing is an effective approach to prevent transfusion reactions by platelet concentrates (PCs). Recently, washed PCs were released by the Japanese Red Cross Society (JRCS).Materials and methods
This retrospective multicenter study evaluated the efficacy and safety of released washed PCs (RWPCs) between September 2016 and January 2017 in Japan. The RWPCs were prepared by washing leukoreduced apheresis PCs with the platelet additive solution, BRS-A, using automated cell processors.Results
Clinical data were obtained from 91 patients and 1210 RWPC transfusions at 50 institutions. The median number of RWPC transfusions per patient was 8 (range, 1–91). RWPCs were used in 94.5% of the patients with a history of recurrent or severe transfusion reactions for preventing such reactions. Responses of RWPCs were evaluated as complete response (91.6%), partial response (8.2%), no-change (0.2%), and progression (0%) and overall response was equal across subgroups divided by patients’ profiles. The median corrected count increment (CCI) at 1 and 24?h post-transfusion were 13.5 (range, 1.9–35.4)?×?109/L and 3.5 (range, ?13 to 53.6)?×?109/L, respectively, and median CCI at 24?h was 5.5 (range, ?13 to 53.6)?×?109/L in patients without risk factors associated with platelet transfusion refractoriness. Transfusion reactions to RWPCs were observed in only nine transfusions (0.7%), all of which were mild allergic reactions.Conclusion
This study demonstrated that RWPCs were effective and safe in patients with a history of transfusion reactions. Further prospective studies on efficacy together with cost-benefit analysis in RWPCs are needed. 相似文献2.
3.
Masanori Daibata Yuiko Nemoto Kentaro Bandobashi Norihiro Kotani Masayuki Kuroda Mutsumi Tsuchiya Heiwa Okuda Tetsuya Takakuwa Shosuke Imai Taro Shuin Hirokuni Taguchi 《Clinical cancer research》2007,13(12):3528-3535
PURPOSE: Bone morphogenetic proteins (BMP), belonging to the transforming growth factor-beta superfamily, are important regulators of cell growth, differentiation, and apoptosis. The biological effects of BMPs on malignant lymphoma, however, remain unknown. Promoter methylation of the BMP-6 gene in lymphomas was investigated. EXPERIMENTAL DESIGN: We investigated BMP-6 promoter methylation and its gene expression in various histologic types of 90 primary lymphomas and 30 lymphoma cell lines. The effect of BMP-6 promoter hypermethylation on clinical outcome was also evaluated. RESULTS: BMP-6 was epigenetically inactivated in subsets of lymphomas. The silencing occurred with high frequency in diffuse large B-cell lymphoma (DLBCL) and Burkitt's lymphoma in association with aberrant BMP-6 promoter methylation. The methylation was observed in 60% (21 of 35) of DLBCL cases and 100% (7 of 7) of DLBCL cell lines, and in 83% (5 of 6) of Burkitt's lymphoma cases and 86% (12 of 14) of Burkitt's lymphoma cell lines. In contrast, other histologic types of primary lymphomas studied had little or no detectable methylation (1 of 49; 2%). The presence of BMP-6 promoter hypermethylation in DLBCL statistically correlated with a decrease in disease-free survival (P = 0.014) and overall survival (P = 0.038). Multivariate analysis showed that the methylation profile was an independent prognostic factor in predicting disease-free survival (P = 0.022) and overall survival (P = 0. 046). CONCLUSION: BMP-6 promoter was hypermethylated more often in aggressive types of lymphomas, and the hypermethylation is likely to be related to the histologic type of lymphomas. BMP-6 promoter methylation may be a potential new biomarker of risk prediction in DLBCL. 相似文献
4.
Fujimaki K Takasaki H Koharazawa H Takabayashi M Yamaji S Baba Y Kanamori H Ishigatsubo Y 《Leukemia & lymphoma》2005,46(7):1101-1102
We report a patient with chronic lymphocytic leukemia (CLL) who developed idiopathic thrombocytopenic purpura (ITP) and myasthenia gravis (MG) after fludarabine therapy. ITP developed after 6 cycles of fludarabine treatment, and MG occurred 2 months after the onset of ITP. MG was successfully treated with immunosuppressive therapy and plasma exchange, while rituximab was effective for CLL and ITP. Fludarabine seemed to have an important role in the onset of ITP and MG in this case. 相似文献
5.
6.
Kuwabara H Kanamori H Takasaki H Takabayashi M Yamaji S Tomita N Fujimaki K Fujisawa S Ishigatsubo Y 《Leukemia & lymphoma》2003,44(7):1235-1237
We report a rare case of involvement of the central nervous system (CNS) by chronic lymphocytic leukemia (CLL). A 68-year-old man with prolymphocytic variant of B-CLL (CLL/PLL), develops CNS involvement with headache and vomiting. Computed tomography of the head showed no abnormalities. The cerebrospinal fluid (CSF) revealed numerous lymphocytoid cells of prolymphocytic appearance consistent with findings on the peripheral blood smear. Immunophenotypic analysis demonstrated that the leukemic B cells were positive for CD19, CD20, and HLA-DR, but CD5 was difficult to detect. The patient was treated with intrathecal methotrexate, cytarabine, and hydrocortisone and had improvement in symptoms and CSF findings. Although CNS involvement is an unusual manifestation in CLL, one should be aware of the possibility of this complication in cases presenting with neurological symptoms. 相似文献
7.
Miyazaki T Fujimaki K Shirasugi Y Yoshiba F Ohsaka M Miyazaki K Yamazaki E Sakai R Tamaru J Kishi K Kanamori H Higashihara M Hotta T Ishigatsubo Y 《American journal of hematology》2007,82(12):1106-1109
Rheumatoid arthritis (RA) is associated with an increased risk of developing lymphoma. Although the pathogenesis is still unclear, the increased risk appears to be related to the high inflammatory activity of RA, immunosuppressive agents, or Epstein-Barr virus (EBV) infection. We investigated the relationship between EBV latent infection and methotrexate (MTX)-associated lymphoma in RA patients. Nine patients were diagnosed with non-Hodgkin's lymphoma (NHL) during MTX treatment for RA in a multicenter study. The pathologic findings were consistent with diffuse large B-cell lymphoma in 8 patients and peripheral T-cell lymphoma, unspecified in 1. EBV infection was detected in 3 patients by in situ hybridization. Among all 9 patients who were initially treated by MTX withdrawal alone, 2 obtained spontaneous complete response (CR), 1 had partial response, 2 had stable disease (SD), and 4 had progressive disease. Both patients who had a CR and 1 who had SD were positive for EBV. Further examination of the latent EBV infection patterns revealed that 2 patients who obtained a CR had latency Type III, and the other with SD had latency Type II. These results demonstrate that immunodeficiency caused by MTX treatment is associated with the development of EBV-related NHL in RA patients. In patients who were treated by MTX for RA and developed NHL, remission can be observed following MTX withdrawal especially in NHL with latency Type III EBV infection. The analysis of EBV infection, including the latency types, is useful to decide the optimum therapeutic strategy. 相似文献
8.
9.
10.
Kurosawa S Yamaguchi T Miyawaki S Uchida N Kanamori H Usuki K Yamashita T Watanabe M Yakushiji K Yano S Nawa Y Taguchi J Takeuchi J Tomiyama J Nakamura Y Miura I Kanda Y Takaue Y Fukuda T 《Blood》2011,117(7):2113-2120
Various prospective trials have been performed to assess the roles of allogeneic hematopoietic cell transplantation (allo-HCT) and chemotherapy in patients with acute myeloid leukemia (AML) in first complete remission (CR1). However, the results have not always been consistent, and there has been a limited evaluation of quality of life (QOL) in these postremission strategies. We performed a Markov decision analysis that enabled us to compare survival outcomes with a QOL evaluation using a database of 2029 adult AML patients who achieved CR1. The Markov decision model compared 2 strategies: allo-HCT or chemotherapy in CR1. Patients who had intermediate- or unfavorable-risk AML had a longer life expectancy when they received allo-HCT in CR1 than patients treated with chemotherapy alone. Likewise, patients who had a suitable related donor who received allo-HCT in CR1 had a longer life expectancy. The life expectancy was shortened to a greater degree by adjustment for QOL in the allo-HCT group. Nevertheless, QOL-adjusted life expectancies in most of the subgroups remained longer in the allo-HCT group than in the chemotherapy group. Our results showed that older patients with a related donor and younger patients with unfavorable cytogenetics benefited the most from allo-HCT in CR1. 相似文献